Nuformix PLC

LSE:NFX (UK)  
£ 0.00 (-2.7%) May 23
At Loss
Market Cap:
£ 1.48M ($ 1.88M)
Enterprise V:
£ 1.27M ($ 1.62M)
Volume:
1.17M
Avg Vol (2M):
1.64M
Also Trade In:
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Nuformix PLC ( ) from 2015 to May 24 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Nuformix PLC stock (LSE:NFX) PE ratio as of May 24 2024 is 0. More Details

Nuformix PLC (LSE:NFX) PE Ratio (TTM) Chart

To

Nuformix PLC (LSE:NFX) PE Ratio (TTM) Historical Data

Total 1192
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Nuformix PLC PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-05-24 At Loss 2024-03-19 At Loss
2024-05-23 At Loss 2024-03-18 At Loss
2024-05-22 At Loss 2024-03-15 At Loss
2024-05-21 At Loss 2024-03-14 At Loss
2024-05-20 At Loss 2024-03-13 At Loss
2024-05-17 At Loss 2024-03-12 At Loss
2024-05-16 At Loss 2024-03-11 At Loss
2024-05-15 At Loss 2024-03-08 At Loss
2024-05-14 At Loss 2024-03-07 At Loss
2024-05-13 At Loss 2024-03-06 At Loss
2024-05-10 At Loss 2024-03-05 At Loss
2024-05-09 At Loss 2024-03-04 At Loss
2024-05-08 At Loss 2024-03-01 At Loss
2024-05-07 At Loss 2024-02-29 At Loss
2024-05-03 At Loss 2024-02-28 At Loss
2024-05-02 At Loss 2024-02-27 At Loss
2024-05-01 At Loss 2024-02-26 At Loss
2024-04-30 At Loss 2024-02-23 At Loss
2024-04-29 At Loss 2024-02-22 At Loss
2024-04-26 At Loss 2024-02-21 At Loss
2024-04-25 At Loss 2024-02-20 At Loss
2024-04-24 At Loss 2024-02-19 At Loss
2024-04-23 At Loss 2024-02-16 At Loss
2024-04-22 At Loss 2024-02-15 At Loss
2024-04-19 At Loss 2024-02-14 At Loss
2024-04-18 At Loss 2024-02-13 At Loss
2024-04-17 At Loss 2024-02-12 At Loss
2024-04-16 At Loss 2024-02-09 At Loss
2024-04-15 At Loss 2024-02-08 At Loss
2024-04-12 At Loss 2024-02-07 At Loss
2024-04-11 At Loss 2024-02-06 At Loss
2024-04-10 At Loss 2024-02-05 At Loss
2024-04-09 At Loss 2024-02-02 At Loss
2024-04-08 At Loss 2024-02-01 At Loss
2024-04-05 At Loss 2024-01-31 At Loss
2024-04-04 At Loss 2024-01-30 At Loss
2024-04-03 At Loss 2024-01-29 At Loss
2024-04-02 At Loss 2024-01-26 At Loss
2024-03-28 At Loss 2024-01-25 At Loss
2024-03-27 At Loss 2024-01-24 At Loss
2024-03-26 At Loss 2024-01-23 At Loss
2024-03-25 At Loss 2024-01-22 At Loss
2024-03-22 At Loss 2024-01-19 At Loss
2024-03-21 At Loss 2024-01-18 At Loss
2024-03-20 At Loss 2024-01-17 At Loss

Nuformix PLC (LSE:NFX) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Nuformix PLC is a pharmaceutical development company. It operates in the field of pharmaceutical development targeting unmet medical needs in fibrosis and oncology via drug repurposing. Its pipeline products include NXP001, NXP002, and NXP004. Geographically, the company operates only in the UK.